Abstract
Background Recent evidence from case reports suggests that a ketogenic diet may be effective for bipolar disorder. To date, no clinical trials have been conducted.
Aims To assess the recruitment and feasibility of a ketogenic diet intervention in bipolar disorder.
Methods Euthymic individuals with bipolar disorder were recruited to a 6-8 week trial of a modified ketogenic diet and a range of clinical, economic and functional outcome measures were assessed.
Results Of 27 recruited participants, 26 commenced and 20 completed the modified ketogenic diet at 6-8 weeks. The completeness of the outcomes dataset was 95% for daily ketone measures, 95% for daily glucose measures and 95% for daily Ecological Momentary Assessment of symptoms during the intervention period. Mean daily blood ketone readings were 1.3 mmol/L (SD= 0.77, Median = 1.1), and 91% of all readings indicated ketosis indicating a high degree of adherence to the diet. Over 91% of daily blood glucose readings were within normal range with 9% indicating mild hypoglycaemia. Eleven minor adverse events were recorded, including fatigue, constipation, drowsiness and hunger. One serious adverse event was reported (euglycemic ketoacidosis in a participant taking SGLT2-inhibitor medication).
Conclusions The recruitment and retention of euthymic individuals with bipolar disorder to a 6-8 week ketogenic diet intervention was feasible, with high outcome measure completion rates. The majority of participants reached and maintained ketosis and adverse events were generally mild and modifiable. A future randomised controlled trial is now warranted.
Study Registration Number ISRCTN61613198
Competing Interest Statement
Dr Iain Campbell has a diagnosis of bipolar disorder and follows a ketogenic diet to manage his symptoms. His current fellowship is funded by the Baszucki Brain Research Fund.
Clinical Trial
ISRCTN61613198
Clinical Protocols
https://www.isrctn.com/editorial/retrieveFile/2a5fdffc-0ed7-4779-8b09-4785e6d69055/41259
Funding Statement
This study was funded by the Baszucki Brain Research Fund.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study received a favourable ethical opinion from the South East Scotland Research Ethics Committee 02
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
3
Blogs/Media
Author Videos